Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP14 | P54578 | 19/20 | 0.70 |
| ▸ | RORC | P51449 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19298011 | 0.89 | USP14 (0.70) | USP14RORC | |
| SCHEMBL18235061 | 0.86 | USP14 (0.66) | USP14RORC | |
| SCHEMBL13740012 | 0.83 | USP14 (1.00) | USP14 | |
| SCHEMBL13741172 | 0.82 | USP14 (1.00) | USP14 | |
| SCHEMBL14152404 | 0.79 | USP14 (1.00) | USP14 | |
| SCHEMBL25712302 | 0.79 | USP14 (0.57) | USP14RORC | |
| SCHEMBL14409138 | 0.79 | RORC (0.58) | USP14RORC | |
| SCHEMBL27921139 | 0.77 | USP14 (0.52) | USP14RORC | |
| SCHEMBL25919164 | 0.77 | USP14 (0.55) | USP14RORC | |
| SCHEMBL16729147 | 0.75 | RORC (0.54) | USP14RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | Kineta, Inc. | 2023-08-03 | — | — | US | disclosed |
| US-11242361-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2020-10-01 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-9850262-B2 | Proteasome activity enhancing compounds | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PROTEOSTASIS THERAPEUTICS, INC. | 2016-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160333031-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | USP14 240/4885RORC 3053/4885 |
| US-20230242557-A9 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | USP14 240/4885RORC 3053/4885 |
| US-11242361-B2 | Proteasome activity enhancing compounds | PSMG3, PSMB1, PSMC1 | USP14 240/4885RORC 3053/4885 |
| US-20200308198-A1 | PROTEASOME ACTIVITY ENHANCING COMPOUNDS | PSMG3, PSMB1, PSMC1 | USP14 240/4885RORC 3053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.